Rivastigmine 1.5mg capsules
Requires a prescription from a doctor or prescriber
Rivastigmine is a parasympathomimetic or cholinergic agent for the treatment of mild to moderate dementia of the Alzheimer's type.
Official documents, adverse reaction reporting, and safety monitoring
Report a side effect
Submit a Yellow Card report to the MHRA
Official medicine documents
Safety monitoring data
Yellow Card reports
The MHRA Yellow Card scheme collects reports of suspected side effects from healthcare professionals and patients. View the Drug Analysis Profile (iDAP) for real-world adverse reaction data.
View Drug Analysis Profile
Suspected adverse reactions reported for Rivastigmine
Browse all iDAP reports
Interactive Drug Analysis Profiles for all medicines
Report a side effect
Submit a Yellow Card report to the MHRA
Data from the MHRA Yellow Card scheme. A reported reaction does not necessarily mean the medicine caused it. Contains public sector information licensed under the Open Government Licence v3.0.
EudraVigilance
The European Medicines Agency (EMA) collects suspected adverse reaction reports from across the EU/EEA through the EudraVigilance system. Search for safety data on this medicine.
View EudraVigilance report
Suspected adverse reactions reported for Rivastigmine
About EudraVigilance
Learn about EU pharmacovigilance and safety monitoring
EudraVigilance data is published by the European Medicines Agency (EMA). A suspected adverse reaction is not necessarily caused by the medicine.
27 branded products available
MHRA licensed products
View all licensed products for Rivastigmine on the MHRA register
Rivastigmine 1.5mg capsules
Rivastigmine 1.5mg capsules
Rivastigmine 1.5mg capsules
Rivastigmine 1.5mg capsules
Rivastigmine 1.5mg capsules
Rivastigmine 1.5mg capsules
Rivastigmine 1.5mg capsules
Rivastigmine 1.5mg capsules
Rivastigmine 1.5mg capsules
Rivastigmine 1.5mg capsules
This is the NHS Drug Tariff indicative price used for reimbursement purposes. It may not reflect the price paid by patients or pharmacies.
View full Drug TariffSource: NHS Drug Tariff via NHSBSA. Derived from dm+d VMPP (Virtual Medicinal Product Pack) pricing data. Contains public sector information licensed under the Open Government Licence v3.0.
WHO defined daily dose (DDD)
9 mg
Not a recommended dose. The DDD is the assumed average maintenance dose per day for a drug used for its main indication in adults. It is a statistical measure used for research and comparison purposes only.
Source: WHO Collaborating Centre for Drug Statistics Methodology, distributed via the NHS dm+d supplementary BNF/ATC mapping files (NHSBSA). Contains public sector information licensed under the Open Government Licence v3.0.
Therapeutically similar medicines
Similarity is based on WHO Anatomical Therapeutic Chemical (ATC) classification and on a factual NHS dm+d therapeutic-grouping code prefix. Source data: NHS dm+d via TRUD (OGL v3.0), WHO ATC/DDD Index.
NHS prescribing volume and spending trends
Guidelines from the National Institute for Health and Care Excellence
NICE clinical guidance(3)
Donepezil, galantamine, rivastigmine and memantine for the treatment of Alzheimer's disease (TA217)
Dementia: assessment, management and support for people living with dementia and their carers (NG97)
Parkinson's disease in adults (NG71)
Source: National Institute for Health and Care Excellence (NICE). Contains public sector information licensed under the Open Government Licence v3.0.
Check stock at pharmacies and supply information
Pharmacy stock checkers
Search for this medicine at major UK pharmacy chains. These links open the retailer's own website — results depend on their current online catalogue.
Supply & safety information
Official UK regulator monitoring and safety alerts
Pharmacy links redirect to the retailer's own search and do not represent real-time stock levels. Shortage and safety information sourced from MHRA drug safety updates (gov.uk, Crown Copyright under OGL v3.0).
Codes for healthcare professionals and prescribing systems
These codes are used by healthcare IT systems and prescribers to identify this medicine.
NHS UK identifiers
Browse tools
SNOMED CT and dm+d codes from NHS TRUD (Technology Reference data Update Distribution), licensed under the Open Government Licence v3.0. BNF code shown is the factual mapping value distributed by NHS Business Services Authority (NHSBSA) in the dm+d supplementary file under OGL v3.0; it is not affiliated with, nor licensed from, the publishers of the British National Formulary. ATC codes from the WHO Collaborating Centre for Drug Statistics Methodology (whocc.no).
Active and completed clinical studies from ClinicalTrials.gov
Source: ClinicalTrials.gov, a database of the U.S. National Library of Medicine (NLM), National Institutes of Health (NIH). Data accessed via ClinicalTrials.gov API v2. Trial information is provided for research purposes and does not constitute medical advice.
Academic studies and reviews for this medicine's active substance
Showing the 50 most relevant studies.
Reviews & meta-analyses: 18 · Randomised trials: 11 · 1998–2026
Showing the 50 most relevant studies, sorted by most relevant.
Dandan Li, Yahong Zhang, Wei Zhang, et al.
Frontiers in Neuroscience, 2019
Chen‐Chen Tan, Jin‐Tai Yu, Hui-Fu Wang, et al.
Journal of Alzheimer s Disease, 2014
- Rivastigmine
- Donepezil
- Alzheimer Disease
Richard A. Hansen, Gerald Gartlehner, Aaron P. Webb, et al.
PubMed, 2008
- Rivastigmine
- Donepezil
- Alzheimer Disease
Mark Bond, G Rogers, J Peters, et al.
Health Technology Assessment, 2012
- Rivastigmine
- Donepezil
- Alzheimer Disease
J Bryant, Andrew Clegg, T. Nicholson, et al.
Health Technology Assessment, 2001
- Rivastigmine
- Donepezil
- Alzheimer Disease
Andrea Takeda, Emma Loveman, Andrew Clegg, et al.
International Journal of Geriatric Psychiatry, 2005
- Rivastigmine
- Donepezil
- Alzheimer Disease
Joanne Rodda, Shirlony Morgan, Zuzana Walker
International Psychogeriatrics, 2009
- Rivastigmine
- Donepezil
- Alzheimer Disease
Emily J. Henderson, Stephen R. Lord, Matthew A. Brodie, et al.
The Lancet Neurology, 2016
- Accidental Falls
- Rivastigmine
- Cholinesterase Inhibitors
Simona Gabriella Di Santo, Federica Prinelli, Fulvio Adorni, et al.
Journal of Alzheimer s Disease, 2013
- Rivastigmine
- Donepezil
- Alzheimer Disease
Craig Ritchie
American Journal of Geriatric Psychiatry, 2004
- Rivastigmine
- Donepezil
- Alzheimer Disease
Sources: aggregated from Europe PMC (EMBL-EBI), OpenAlex, Crossref, PubMed and other open scholarly databases. Retracted articles are excluded. Study information is provided for research purposes and does not constitute medical advice.
Pharmacology and chemical data from DrugBank
Key facts
Drug status
Approved
Major interactions
None known
Half-life
1.5 hours
Mechanism
Rivastigmine is a carbamate derivative that is structurally related to physostigmine, but not to donepezil and tacrine.
Food interactions
1 warning
Human targets
2 targets
Data: DrugBank · CC BY-NC 4.0
Pharmacokinetics at a glance
Half-life
1.5 hours
Protein binding
40%
Volume of distribution
1.8 to 2.7 L/kg
Metabolism
Elimination
1%
Clearance
2.1-2.8 L/h
Pharmacokinetic data: DrugBank · CC BY-NC 4.0
Known interactions with other medications. Always consult a healthcare professional.
Showing 50 of 393 interactions
How the body processes this drug — absorption, distribution, metabolism, and elimination
Proteins and enzymes this drug interacts with in the body
ATC N06DA03
Chemical identifiers
CAS, UNII, InChI Key and database cross-references
Show
Chemical identifiers
CAS, UNII, InChI Key and database cross-references
Linked compound data from DrugBank Open Data (CC BY-NC 4.0)
Rivastigmine
Additional database identifiers
Drugs Product Database (DPD)
11987
ChemSpider
70377
BindingDB
11682
ZINC
ZINC000000004413
HUGO Gene Nomenclature Committee (HGNC)
HGNC:108
GenAtlas
ACHE
GeneCards
ACHE
GenBank Gene Database
M55040
GenBank Protein Database
177975
Guide to Pharmacology
2465
UniProt Accession
ACES_HUMAN
HUGO Gene Nomenclature Committee (HGNC)
HGNC:983
GenAtlas
BCHE
GeneCards
BCHE
GenBank Gene Database
M32391
GenBank Protein Database
1311630
Guide to Pharmacology
2471
UniProt Accession
CHLE_HUMAN
DrugBank citations
If you use DrugBank data in your research, please cite the following publications:
Show earlier publications
Structured knowledge from the free knowledge base
ATC classifications (Wikidata)
Linked open data from Wikidata (Q411887), a free and open knowledge base operated by the Wikimedia Foundation. Data is available under the Creative Commons CC0 1.0 Public Domain Dedication. WHO INN from the World Health Organization.